Maraviroc Switch Renal Substudy: A substudy of MARCH, a randomised, open-label study to evaluate the efficacy and safety of maraviroc (MVC) as a switch for either nucleoside or nucleotide analogue reverse transcriptase inhibitors (N(t) RTI) or boosted protease inhibitors (PI/r) in HIV-1 infected individuals with stable, well-controlled plasma HIV-RNA while taking their first(N(t)RTI) + PI/r regimen of combination antiretroviral therapy (cART).

Trial Profile

Maraviroc Switch Renal Substudy: A substudy of MARCH, a randomised, open-label study to evaluate the efficacy and safety of maraviroc (MVC) as a switch for either nucleoside or nucleotide analogue reverse transcriptase inhibitors (N(t) RTI) or boosted protease inhibitors (PI/r) in HIV-1 infected individuals with stable, well-controlled plasma HIV-RNA while taking their first(N(t)RTI) + PI/r regimen of combination antiretroviral therapy (cART).

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Maraviroc (Primary) ; HIV protease inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms MARCH-renal
  • Most Recent Events

    • 19 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 19 Dec 2013 Accrual to date is 5% according to United Kingdom Clinical Research Network.
    • 17 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top